Canada Pension Plan Investment Board Increases Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Canada Pension Plan Investment Board increased its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 417.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 45,000 shares of the company's stock after purchasing an additional 36,300 shares during the quarter. Canada Pension Plan Investment Board owned 0.10% of Pacira BioSciences worth $848,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of PCRX. Sterling Capital Management LLC raised its stake in shares of Pacira BioSciences by 779.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after buying an additional 1,208 shares during the period. Caitlin John LLC raised its position in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after acquiring an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Pacira BioSciences by 495.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after purchasing an additional 513 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Pacira BioSciences by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company's stock worth $184,000 after purchasing an additional 918 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company's stock.

Pacira BioSciences Trading Down 0.7 %

Shares of Pacira BioSciences stock traded down $0.19 during trading hours on Tuesday, hitting $26.96. The company's stock had a trading volume of 388,592 shares, compared to its average volume of 893,762. The firm has a fifty day moving average of $24.52 and a 200-day moving average of $21.61. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -13.28 and a beta of 0.71. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67.

Analysts Set New Price Targets

Several research firms recently issued reports on PCRX. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their price objective for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. HC Wainwright boosted their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research report on Tuesday, April 8th. Needham & Company LLC restated a "buy" rating and issued a $32.00 price objective on shares of Pacira BioSciences in a report on Tuesday, April 8th. Barclays upped their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $26.67.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.